Ishara Investments LP Buys Shares of 24,000 Tarsus Pharmaceuticals, Inc. $TARS

Ishara Investments LP purchased a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) during the fourth quarter, HoldingsChannel reports. The firm purchased 24,000 shares of the company’s stock, valued at approximately $1,965,000. Tarsus Pharmaceuticals accounts for 2.3% of Ishara Investments LP’s portfolio, making the stock its 16th biggest position.

Several other institutional investors also recently modified their holdings of TARS. Comerica Bank increased its holdings in Tarsus Pharmaceuticals by 470.0% in the fourth quarter. Comerica Bank now owns 855 shares of the company’s stock valued at $70,000 after purchasing an additional 705 shares during the period. Truvestments Capital LLC increased its holdings in Tarsus Pharmaceuticals by 106.1% in the fourth quarter. Truvestments Capital LLC now owns 909 shares of the company’s stock valued at $74,000 after purchasing an additional 468 shares during the period. Osaic Holdings Inc. increased its holdings in Tarsus Pharmaceuticals by 779.1% in the second quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock valued at $113,000 after purchasing an additional 2,462 shares during the period. Leonteq Securities AG acquired a new stake in Tarsus Pharmaceuticals in the fourth quarter valued at $164,000. Finally, Tower Research Capital LLC TRC increased its holdings in Tarsus Pharmaceuticals by 220.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,045 shares of the company’s stock valued at $164,000 after purchasing an additional 2,782 shares during the period. Institutional investors own 90.01% of the company’s stock.

Insider Transactions at Tarsus Pharmaceuticals

In related news, Director Katherine Goodrich sold 2,954 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $62.08, for a total value of $183,384.32. Following the transaction, the director owned 2,233 shares of the company’s stock, valued at approximately $138,624.64. This trade represents a 56.95% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director William J. Phd Link sold 12,500 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $62.12, for a total transaction of $776,500.00. Following the completion of the transaction, the director directly owned 106,786 shares in the company, valued at approximately $6,633,546.32. The trade was a 10.48% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 29,850 shares of company stock valued at $1,837,321 over the last three months. Corporate insiders own 9.64% of the company’s stock.

Wall Street Analyst Weigh In

TARS has been the subject of a number of recent research reports. Oppenheimer initiated coverage on Tarsus Pharmaceuticals in a report on Friday, April 24th. They issued an “outperform” rating and a $98.00 price objective for the company. Wall Street Zen upgraded Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, June 6th. Lifesci Capital upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Monday, March 16th. HC Wainwright restated a “buy” rating and issued a $88.00 price objective on shares of Tarsus Pharmaceuticals in a report on Monday, May 4th. Finally, Guggenheim increased their price objective on Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $90.67.

Tarsus Pharmaceuticals Trading Up 2.9%

TARS opened at $62.55 on Thursday. Tarsus Pharmaceuticals, Inc. has a 1-year low of $38.51 and a 1-year high of $85.25. The company has a current ratio of 3.74, a quick ratio of 3.71 and a debt-to-equity ratio of 0.21. The company has a market cap of $2.69 billion, a P/E ratio of -54.87 and a beta of 0.49. The company has a fifty day moving average price of $63.47 and a two-hundred day moving average price of $69.54.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.24. Tarsus Pharmaceuticals had a negative net margin of 9.02% and a negative return on equity of 14.19%. The firm had revenue of $162.05 million during the quarter, compared to the consensus estimate of $149.60 million. Analysts predict that Tarsus Pharmaceuticals, Inc. will post -0.59 EPS for the current fiscal year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.